We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group.
Archives of Ophthalmology 1986 May
The Macular Photocoagulation Study randomized controlled clinical trials designed to determine whether argon laser photocoagulation is effective for preventing or delaying severe visual loss in eyes with an extrafoveal choroidal neovascular membrane secondary to senile macular degeneration (Senile Macular Degeneration Study [SMDS]), ocular histoplasmosis (Ocular Histoplasmosis Study [OHS]), or idiopathic neovascularization (Idiopathic Neovascularization Study [INVS]). Eligible patients were assigned randomly to a "treatment" group or to a "no treatment" group until recruitment was terminated in 1982 (SMDS) and 1983 (OHS and INVS) because of demonstrated short-term treatment benefit. As of Aug 31, 1985, three or more years of scheduled follow-up examinations had been completed for 208 (88%) of 236 eyes in the SMDS, 203 (77%) of 262 eyes in the OHS, and 51 (76%) of 67 eyes in the INVS. The relative risk of experiencing severe loss of vision after three years in eyes initially assigned to the no treatment group in comparison with eyes assigned to the argon laser photocoagulation group was 1.4 in the SMDS (95% confidence interval [CI]: 1.1 to 1.9), 5.5 in the OHS (95% CI: 3.9 to 10.8), and 2.3 in the INVS (95% CI: 0.8 to 6.5). The beneficial effects of argon laser treatment have persisted in all three studies in spite of the fact that some eyes in the "no treatment" groups were treated later in their clinical course as a result of the evidence of early benefit. Follow-up of all patients continues so that treatment effectiveness over a five-year period can be assessed.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app